Evidence map›Paper›PMID 27959316›Full record

ReviewAACN advanced critical care2016

Clostridium difficile Infection and Fecal Microbiota Transplant.

Alyssa Liubakka, Byron P Vaughn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AACN advanced critical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Pro-Inflammatory Cytokines Enhanced In Vitro Cytotoxic Activity ofInternational journal of molecular sciences · 2024
    Article
  12. Review
  13. Microorganisms · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Fidaxomicin Use in the Pediatric Population withClinical pharmacology : advances and applications · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alyssa LiubakkaAlyssa Liubakka is an Internal Medicine Resident, Department of Medicine, University of Minnesota, 420 Delaware Street SE, MMC 284, Minneapolis, MN 55455 (e-mail: liuba006@umn.edu). Byron P. Vaughn is an Assistant Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, and part of the Microbiota Therapeutics Program, University of Minnesota, Minneapolis, Minnesota.
Byron P VaughnAlyssa Liubakka is an Internal Medicine Resident, Department of Medicine, University of Minnesota, 420 Delaware Street SE, MMC 284, Minneapolis, MN 55455 (e-mail: liuba006@umn.edu). Byron P. Vaughn is an Assistant Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, and part of the Microbiota Therapeutics Program, University of Minnesota, Minneapolis, Minnesota.

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
NCATS NIH HHS UL1 TR000114NIDDK NIH HHS L30 DK099831
6 · The paper itself

Abstract

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent CDI. This review covers the current epidemiology of CDI (including toxigenic and nontoxigenic strains, risk factors for infection, and recurrent infection), methods of diagnosis, existing first-line therapies in CDI, the role of fecal microbiota transplant for multiple recurrent CDIs, and the potential use of fecal microbial transplant for patients with severe or refractory infection.

Indexed as

Fecal Microbiota TransplantationMicrobiotaAdultAgedAged, 80 and overClostridioides difficileClostridium InfectionsEducation, Medical, ContinuingFecesFemaleHumansMaleMiddle AgedRisk FactorsTreatment OutcomeUnited StatesClostridium difficile infectionfecal microbiota transplantfecal transplantrecurrent C difficile infection

Identifiers

PMID27959316
PMCPMC5666691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.